Breathing Easy: Conquering Obstructive Sleep Apnea for Better Health - Screening and Management of OSA

Estimated Time
0.5 hr

Release Date
Feb 21, 2024

Expiration Date
Feb 20, 2025

Obstructive Sleep Apnea (OSA) is a prevalent but often underestimated sleep disorder with significant implications for the health and well-being of individuals in the United States. Despite its impact on chronic diseases and healthcare costs, OSA remains underdiagnosed, leading to untreated sleep apnea and its consequences. With emerging strategies for OSA treatment, it's crucial for healthcare providers to stay informed about the latest clinical evidence shaping the treatment landscape.

Explore the 3-part on-demand series, Breathing Easy: Conquering Obstructive Sleep Apnea for Better Health. This collaborative effort, in conjunction with local AAFP Chapter meetings, provides expert guidance and clinical best practices for screening, managing, monitoring, and treating patients with OSA. Key topics in Part 2: Screening and Management of OSA include:

  • Evaluating sleep health and identifying patients at-risk for OSA: Establishing routine sleep health evaluation and best practices for assessments and screening to promptly recognize OSA patients
  • Recognizing diverse presentations of OSA: Typical vs atypical presentation of OSA symptoms, distinguishing phenotypes, validated assessment and screening tools, evidence-based guidelines for screening and diagnosis to identify diverse presentations of OSA
  • Individualizing OSA management plans: Strategies to personalize treatment plans, including new and emerging options, based on patient factors, disease phenotype, comorbidities, etc. and engaging patients in treatment decisions

Be sure to take part 1 and part 3 to maximze your education and impact!

Speakers

Accreditation and Disclosure Information

Educational Objectives
After completing this activity, the participant should be better able to:

  • Incorporate evidence-based approaches including, routine evaluation of sleep history to promptly identify signs of OSA.
  • Identify distinct phenotypes of OSA including typical and atypical presentations to initiate timely screening and diagnosis, raise awareness, and educate patients on OSA and associated complications.
  • Evaluate the effectiveness of current and emerging treatment modalities for management of OSA, including behavioral lifestyle changes, devices, and pharmacotherapies.
  • Apply multidisciplinary care coordination strategies to promote patient-centered OSA care.

Program Agenda

  • Evaluating sleep health and identifying patients at-risk for OSA
    Establishing routine sleep health evaluation and best practices for assessments and screening to promptly recognize OSA patients
  • Recognizing diverse presentations of OSA
    Typical vs atypical presentation of OSA symptoms, distinguishing phenotypes, validated assessment and screening tools, evidence-based guidelines for screening and diagnosis to identify diverse presentations of OSA
  • Individualizing OSA management plans
    Strategies to personalize treatment plans, including new and emerging options, for each patient based on patient factors, disease phenotype, comorbidities, etc. and engaging patients in treatment decision making
     

Target Audience
This activity is directed towards primary care physicians and healthcare providers who interface with patients with OSA, including patients with associated health comorbidities (eg, obesity, CVD, T2D, etc).

Accreditation, Support and Credit

 

 

Joint Accreditation with Commendation Logo

In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

AAFP CME Credit
Joint Accreditation with Commendation LogoThe AAFP has reviewed Breathing Easy: Conquering Obstructive Sleep Apnea for Better Health - Screening and Management of OSA and deemed it acceptable for up to 0.50 Enduring Materials, Self-Study AAFP Prescribed credits. Term of Approval is from 02/21/2024 to 02/20/2025. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Physician Associate
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until February 20, 2025. PAs should only claim credit commensurate with the extent of their participation.

 

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Commercial Support Statement
This activity is supported by an educational grant from Lilly.

Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc. is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

Faculty Disclosures
Chair/Planner/Presenter
Paul P. Doghramji, MD, FAAFP
Senior Family Practice Physician
Collegeville Family Practice
Medical Director, Wellness Center,
Ursinus College
Collegeville, PA

Paul P. Doghramji, MD, FAAFP, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AstraZeneca, Axsome, Idorsia
Speakers’ Bureau: Axsome, Idorsia
Stock Ownership: CVS, Pfizer

Planner/Presenter
Eric L. Johnson, MD

Professor
University of North Dakota
School of Medicine and Health Sciences
Assistant Medical Director
Altru Diabetes Center
Grand Forks, ND

Eric L. Johnson, MD, has no relevant financial relationships with ineligible companies to disclose for this educational activity.

All of the relevant financial relationships of individuals for this activity have been mitigated.

Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and the activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.

For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board. If you have questions regarding your certificate, please contact via email at mvu@mlieducation.org.

For Physicians, if requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.

About This Activity
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.

Copyright © 2024 Medical Learning Institute, Inc. All Rights Reserved.